AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11700812
Drug: Placebo (0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.03 g vitamin C)
Trial: 9424970
Drug: Intraarticular morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarticular morphine (small doses)
Trial: 9424970
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of intraarticular morphine and bupivacaine
Trial: 9424970
Drug: Adrenaline addition,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline addition, tourniquet use, time interval between injection and tourniquet release
Trial: 7962426
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with 200 x 10(6) purified paternal lymphocytes before pregnancy
Trial: 3239463
Drug: Control condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control condition (no further treatment)
Trial: 25575728
Drug: Montelukast (4mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (4mg daily for 5 days)
Trial: 24085051
Drug: Topical regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical regimen (2% hydroquinone, 1% hydrocortisone and 0.05% tretinoin) with serial glycolic acid peeling
Trial: 24085051
Drug: Topical regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical regimen (2% hydroquinone, 1% hydrocortisone, 0.05% tretinoin)
Trial: 18439174
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy plus additional tilt training sessions
Trial: 16714461
Drug: Theophylline (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (200 mg 30 minutes before contrast medium administration)
Trial: 16714461
Drug: Acetylcysteine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylcysteine (600 mg twice daily on the day of and the day before the examination)
Trial: 16714461
Drug: Both agents
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both agents combined (theophylline and acetylcysteine)
Trial: 15534843
Drug: Lipid lowering
RxNorm normalized name: Lipid lowering agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid lowering drug
Trial: 11282901
Drug: Low-dose metoprolol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose metoprolol CR/XL (25 mg once daily)
Trial: 21315352
Drug: Fluvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin (40 mg once daily)
Trial: 3324497
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg nicergoline h.s.
Trial: 3324497
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg nicergoline b.i.d.
Trial: 26503414
Drug: Sofosbuvir 400
RxNorm normalized name: sofosbuvir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir 400 mg once daily plus ribavirin 1000-1200 mg divided twice daily for 12 weeks
Trial: 26503414
Drug: Sofosbuvir 400
RxNorm normalized name: sofosbuvir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir 400 mg once daily plus ribavirin 1000-1200 mg divided twice daily for 16 weeks
Trial: 26503414
Drug: Sofosbuvir 400
RxNorm normalized name: sofosbuvir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir 400 mg once daily plus ribavirin 1000-1200 mg divided twice daily for 24 weeks
Trial: 25237196
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of 50 μg varicella-zoster virus glycoprotein E (gE) adjuvanted with AS01B
Trial: 25237196
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of gE adjuvanted with AS01E
Trial: 25237196
Drug: 1 dose
RxNorm normalized name: Ribose 3 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of saline followed by 2 doses of gE/AS01B
Trial: 25237196
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of saline
Trial: 18809614
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with paclitaxel 200 mg/m² and carboplatin AUC 6 mg/mL/min every 3 weeks for four cycles
Trial: 16278616
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg micronized 17beta‐estradiol daily
Trial: 9860147
Drug: Enalapril (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (0.5 mg) at pH 5
Trial: 9860147
Drug: Lisinopril (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (0.5 mg) at pH 6
Trial: 9860147
Drug: Enalapril (0.06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (0.06 mmol x l(‐1)) with cephradine (0.05 mmol x l(‐1))
Trial: 9860147
Drug: Lisinopril (0.057
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (0.057 mmol x l(‐1)) with cephradine (0.05 mmol x l(‐1))
Trial: 7884114
Drug: Psyllium fiber
RxNorm normalized name: Konsyl Daily Psyllium Fiber
DrugBank: Plantago seed (DB11097)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psyllium fiber (Metamucil) 3.4 g
Trial: 2404487
Drug: 0.008% timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.008% timolol ophthalmic solution
Trial: 2404487
Drug: 0.25% timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% timolol ophthalmic solution
Trial: 25322473
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (control group, N=65)
Trial: 17383283
Drug: NT-proBNP (highest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT-proBNP (highest quartile > or = 1170 ng/L for men, > or = 2150 ng/L for women)
Trial: 15576015
Drug: Sibutramine 15
RxNorm normalized name: sibutramine 15 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine 15 mg administered orally under fasting conditions
Trial: 15576015
Drug: Sibutramine 15
RxNorm normalized name: sibutramine 15 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine 15 mg administered orally under fed conditions
Trial: 15576015
Drug: Sibutramine 15
RxNorm normalized name: sibutramine 15 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine 15 mg administered orally with food
Trial: 7888977
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch treatment
Trial: 3242578
Drug: Apomorphine (0.009
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apomorphine (0.009 mg kg‐1 subcutaneous route)
Trial: 3242578
Drug: Yohimbine (0.30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine (0.30 mg kg‐1 i.v. route)
Trial: 28052841
Drug: Web-based guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based guided self-help intervention (cognitive-behavioral therapy and problem-solving therapy) in addition to usual care
Trial: 23578686
Drug: Mitii training
RxNorm normalized name: Strychnos mitis whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitii training (20 weeks, 30 min daily)
Trial: 16769956
Drug: No dopamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No dopamine agonists
Trial: 16769956
Drug: Potent D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potent D3 receptor agonist
Trial: 15315398
Drug: Grape seed
RxNorm normalized name: grape seed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grape seed extract (1000 mg/day total polyphenols)
Trial: 11503008
Drug: Erythromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (500 mg, 3 times daily for 4 days)
Trial: 11503008
Drug: DHEC (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEC (10 mg, administered alone)
Trial: 9250182
Drug: Conventional radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional radiotherapy - 30 fractions of 2 Gy for a total dose of 60 Gy in 6 weeks
Trial: 8487006
Drug: Low-salt intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-salt intake (2.8 +/- 1.0 g day-1 of NaCl)
Trial: 8487006
Drug: Salt supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salt supplements (11.7 +/- 2.5 g day-1 of NaCl)
Trial: 3661951
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of an opioid prior to methohexital and addition of lidocaine to the methohexital solution
Trial: 29895330
Drug: Dapagliflozin (5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin (5-10 mg/day)
Trial: 29895330
Drug: Sitagliptin (50-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin (50-100 mg/day)
Trial: 15175214
Drug: Topical lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine 2% gel
Trial: 16354850
Drug: Omega-3 PUFA-rich
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 PUFA-rich supplement (400 kilocalories per day)
Trial: 16354850
Drug: Omega-3 PUFA-rich
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 PUFA-rich supplement
Trial: 16354850
Drug: Omega-3 PUFA-nonrich
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 PUFA-nonrich supplement
Trial: 12552051
Drug: Droperidol 2.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 2.75 mg
Trial: 12552051
Drug: Droperidol 5.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 5.5 mg
Trial: 12552051
Drug: Droperidol 8.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 8.25 mg
Trial: 9448552
Drug: Zileuton 400
RxNorm normalized name: Zileuton
DrugBank: Zileuton (DB00744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zileuton 400 mg 4 times daily
Trial: 9448552
Drug: Zileuton 600
RxNorm normalized name: zileuton 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zileuton 600 mg 4 times daily
Trial: 9448552
Drug: Theophylline (dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (dosage titrated to achieve trough concentrations of 8 to 15 micrograms/mL)
Trial: 2615523
Drug: Morning intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning intravenous administration of 4' epi-adriamycin (45 mg m-2)
Trial: 2615523
Drug: Afternoon intravenous
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Afternoon intravenous administration of 4' epi-adriamycin (45 mg m-2)
Trial: 2615523
Drug: Morning and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning and afternoon dosing of 4' epi-adriamycin
Trial: 21983248
Drug: TPA (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPA (25 μg)
Trial: 21983248
Drug: IVB (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVB (1.25 mg of bevacizumab)
Trial: 8285365
Drug: Ozone therapy
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone therapy (endovenous)
Trial: 8285365
Drug: Ozone therapy
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone therapy (intramuscular)
Trial: 8285365
Drug: Ozone therapy
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone therapy (rectal)
Trial: 22921698
Drug: Daily vardenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily vardenafil 10 mg
Trial: 18514907
Drug: Urtica dioica
RxNorm normalized name: Urtica Dioica
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urtica dioica (nettle sting) daily for 1 week
Trial: 18514907
Drug: Urtica galeopsifolia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urtica galeopsifolia (placebo) daily for 1 week
Trial: 15452188
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa (40,000 U once weekly)
Trial: 12616254
Drug: New MOW
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New MOW program (3 meals and 2 snacks per day, 7 days a week, meeting 100% of the Daily Reference Intake)
Trial: 12616254
Drug: Traditional MOW
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional MOW program (5 hot meals per week, meeting 33% of the Daily Reference Intake)
Trial: 26554025
Drug: Prasugrel (potent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (potent irreversible P2Y12 inhibitor)
Trial: 18271227
Drug: Chinese drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese drugs acupoint injection (Danshen Injection and Chaihu Injection)
Trial: 18271227
Drug: Saline acupoint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline acupoint injection
Trial: 18271227
Drug: Huichun Ruyi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huichun Ruyi capsules
Trial: 16302325
Drug: 1% clindamycin/zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% clindamycin/zinc gel applied once daily
Trial: 16302325
Drug: 1% clindamycin/zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% clindamycin/zinc gel applied twice daily
Trial: 16302325
Drug: 1% clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% clindamycin lotion applied twice daily
Trial: 12044272
Drug: TyphimVi and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TyphimVi and YF‐VAX on day 0 and an optional dose of VAQTA 1 month later (Group 2)
Trial: 2508161
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg orally administered diazepam
Trial: 202346
Drug: Clozapine 25
RxNorm normalized name: clozapine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozapine 25 mg/night for three consecutive nights
Trial: 29976582
Drug: Alteplase treatment
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alteplase treatment decision based on NIHSS scores
Trial: 29976582
Drug: Factors influencing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Factors influencing treatment decisions
Trial: 22892110
Drug: Nitrofurantoin 100
RxNorm normalized name: nitrofurantoin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrofurantoin 100 mg twice a day for 5 consecutive days
Trial: 22892110
Drug: Placebo 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 100 mg twice a day for 5 consecutive days
Trial: 20706917
Drug: Panic Control
RxNorm normalized name: BENZALKONIUM CHLORIDE 1 g in 59 mL TOPICAL GEL [Donut Panic Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panic Control Treatment for Adolescents (PCT‐A)
Trial: 17954368
Drug: Amlodipine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine alone after discontinuation of Quinapril for 6 weeks
Trial: 16135167
Drug: N-acetylcysteine (352
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (352 mg per day)
Trial: 16135167
Drug: Bromhexine hydrochloride
RxNorm normalized name: bromhexine hydrochloride
DrugBank: Bromhexine (DB09019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromhexine hydrochloride (4 mg per day)
Trial: 23278355
Drug: Moderate dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate dose of alcohol (breath alcohol concentration 50 mg/dl)
Trial: 14992558
Drug: Oats-containing gluten-free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oats-containing gluten-free diet (50 g daily)
Trial: 10584476
Drug: Dexamethasone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.5 mg/kg/day for 5 days, tapered progressively)
Trial: 28072459
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy (CBT) alone
Trial: 31318392
Drug: Durvalumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab plus tremelimumab combination therapy (1500 mg durvalumab every 4 weeks and 75 mg tremelimumab every 4 weeks for 4 cycles, followed by durvalumab monotherapy for up to 12 months)
Trial: 31318392
Drug: Durvalumab monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab monotherapy (1500 mg every 4 weeks for up to 12 months)
Trial: 17545007
Drug: No induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No induction therapy
Trial: 15716702
Drug: 20 mg/day
RxNorm normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day enalapril (ACE inhibitor)
Trial: 10530414
Drug: Roquinimex (Linomide),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roquinimex (Linomide), 0.2 mg/kg body weight, twice weekly for 2 years
Trial: 2031798
Drug: Sodium diatrizoate
RxNorm normalized name: Diatrizoate Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium diatrizoate (ionic monomer) at 150 mg I/ml (726 mosmol/kg)
Trial: 29161417
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (50,000 IU oral weekly for 12 weeks)
Trial: 29161417
Drug: Placebo (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral weekly for 12 weeks)
Trial: 26879279
Drug: AMG 334
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 334 70 mg
Trial: 26879279
Drug: AMG 334
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 334 7 mg
Trial: 26879279
Drug: AMG 334
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 334 21 mg
Trial: 22339125
Drug: Darunavir/ritonavir (DRV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darunavir/ritonavir (DRV/r) 600/100 mg bid
Trial: 22339125
Drug: Lopinavir/ritonavir (LPV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir (LPV/r) 400/100 mg bid
Trial: 20540443
Drug: Diazepam (5-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (5-40 mg) and Flumazenil (0.36 mg)
Trial: 20540443
Drug: Flumazenil (0.36
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (0.36 mg)
Trial: 1483797
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 mg slow release every 8 hours)
Trial: 6364778
Drug: Multiagent chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiagent chemotherapy including cyclophosphamide, imidazolecarboxamide, and vincristine given in 5-day pulses each month for 12 courses.
Trial: 6364778
Drug: Multiagent chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiagent chemotherapy (as prescribed).
Trial: 6364778
Drug: Previous treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous treatment regimen from study CCG 011 (no chemotherapy or oral CPM).
Trial: 22683137
Drug: Glimepiride once
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glimepiride once daily
Trial: 15841092
Drug: Lactobacillus acidophilus
RxNorm normalized name: Lactobacillus acidophilus
DrugBank: Lactobacillus acidophilus (DB15823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus acidophilus (3 x 10^10 CFU, two capsules, three times a day for 6 weeks)
Trial: 15841092
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two capsules, three times a day for 6 weeks)
Trial: 12469331
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg albendazole
Trial: 9585394
Drug: Fasting plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting plasma glucose > or = 10.0 mmol/l
Trial: 9585394
Drug: Fasting plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting plasma glucose > or = 7.8 mmol/l to < 10.0 mmol/l
Trial: 9585394
Drug: Fasting plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting plasma glucose < 7.8 mmol/l
Trial: 2817307
Drug: Turbuhaler (terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Turbuhaler (terbutaline inhalation)
Trial: 2817307
Drug: Nebuhaler (terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebuhaler (terbutaline inhalation)
Trial: 51664
Drug: Heparinoid cream
RxNorm normalized name: heparinoids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparinoid cream
Trial: 31492999
Drug: Assessment of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assessment of supplement samples
Trial: 27879193
Drug: Flumagen® 370
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumagen® 370 mg tablet
Trial: 27879193
Drug: Somalgen® 370
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somalgen® 370 mg tablet
Trial: 25389489
Drug: Oral education
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral education program
Trial: 17575467
Drug: Losartan (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (100 mg/day) + Pioglitazone (30 mg/day)
Trial: 8961475
Drug: Dexamethasone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (20 mg) in addition to ondansetron (8 mg three times a day)
Trial: 8961475
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in addition to ondansetron (8 mg three times a day)
Trial: 1742515
Drug: nizatidine 150
RxNorm normalized name: nizatidine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nizatidine 150 mg